CMS’ GLP-1 Bridge Demonstration—Questions and Potential Consequences

This Viewpoint discusses the US Centers for Medicare & Medicaid Services’ (CMS) extension of the Medicare Glucagon-Like Peptide-1 (GLP-1) Bridge and outlines unanswered questions related to how the bridge will affect Medicare.

Authors

Institutions

Publication Details

Journal
JAMA
Published
2026-06-24
DOI
https://doi.org/10.1001/jama.2026.11253
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

CMS’ GLP-1 Bridge Demonstration—Questions and Potential Consequences

Rachel E. Sachs, Kristi Martin
JAMA
Diabetes Treatment and Management
article

CMS’ GLP-1 Bridge Demonstration—Questions and Potential Consequences

Rachel E. Sachs, Kristi Martin
article en

Abstract

This Viewpoint discusses the US Centers for Medicare & Medicaid Services’ (CMS) extension of the Medicare Glucagon-Like Peptide-1 (GLP-1) Bridge and outlines unanswered questions related to how the bridge will affect Medicare.

JAMA
Federal Highway Administration (US), Washington University in St. Louis (US), CCCC Highway Consultants (China) (CN)
Openalex Percentile: Top 8%
Diabetes Treatment and Management
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

CMS’ GLP-1 Bridge Demonstration—Questions and Potential Consequences — Rachel E. Sachs, Kristi Martin · JAMA (2026) | TGRS Research Map | TGRS